AbbVie Inc.

Applied Therapeutics Announces Appointment of Dr. Chuck Silberstein, MD, MBA, CFA as Chief Financial Officer and Head of Business Development

Retrieved on: 
Tuesday, May 26, 2020
Companies, Allergan, AbbVie Inc., Columbia Business School, Master of Business Administration, Silberstein

Dr. Silberstein is replacing Dr. Mark Vignola, who will be moving on to pursue new business opportunities.

Key Points: 
  • Dr. Silberstein is replacing Dr. Mark Vignola, who will be moving on to pursue new business opportunities.
  • His experience across all aspects of the business, including corporate strategy and business development, solidifies our capabilities as we move forward.
  • Dr. Silberstein was formerly Senior Vice President of Corporate Business Development at Allergan plc (recently acquired by AbbVie).
  • Dr. Silberstein received his MD from Albert Einstein College of Medicine and his MBA from Columbia Business School.

Research Report with COVID-19 Forecasts- Gastrointestinal Diseases Therapeutics Market 2020-2024 | Increasing Incidence of Gastrointestinal Diseases to Boost Growth | Technavio

Retrieved on: 
Friday, May 22, 2020
General Health, Pharmaceutical, Health, Companies, Health, Boehringer Ingelheim, AbbVie Inc., AstraZeneca, Pharmaceutical industry

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43343

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43343
    Gastrointestinal Diseases Therapeutics Market 2020-2024: Scope
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our gastrointestinal diseases therapeutics market report covers the following areas:
    This study identifies strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years.
  • Gastrointestinal Diseases Therapeutics Market 2020-2024: Vendor Analysis
    We provide a detailed analysis of vendors operating in the gastrointestinal diseases therapeutics market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA Backed with competitive intelligence and benchmarking, our research reports on the gastrointestinal diseases therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Gastrointestinal Diseases Therapeutics Market 2020-2024: Key Highlights

A Safe Haven Foundation Receives Donation from The AbbVie COVID-19 $5 Million Dollar Community Resilience Fund To Tackle Healthcare For The Homeless

Retrieved on: 
Friday, May 22, 2020
Homelessness, Housing, Humanitarian aid, Poverty, Socioeconomics, AbbVie Inc., Haven, Safe haven, Companies, Articles, Structure

CHICAGO, May 21, 2020 /PRNewswire-PRWeb/ -- A Safe Haven Foundation (ASHF) has been selected as one of 26 nonprofit organizations to receive a donation from the $5 million AbbVie COVID-19 Community Resilience Fund.

Key Points: 
  • CHICAGO, May 21, 2020 /PRNewswire-PRWeb/ -- A Safe Haven Foundation (ASHF) has been selected as one of 26 nonprofit organizations to receive a donation from the $5 million AbbVie COVID-19 Community Resilience Fund.
  • The Center provides homeless individuals with a safe environment to shelter-in-place and also receive the healthcare, behavioral healthcare, nutrition, and support they need.
  • A Safe Haven is an anchor organization and considered the largest single integrated model serving and meeting the needs of the homeless in Chicago.
  • A Safe Haven has not experienced a COVID-19 outbreak because of its unique semi-private suites and rigorous infection control policies.

AbbVie Announces 26 Nonprofits Selected for the COVID-19 Community Resilience Fund

Retrieved on: 
Thursday, May 21, 2020
Health, Motivation, Psychological resilience, Self-sustainability, Articles, Direct Relief, AbbVie Inc., Companies

Through support from the newly created AbbVie COVID-19 Community Resilience Fund, these organizations will help front-line healthcare workers and vulnerable populations in hard-hit communities.

Key Points: 
  • Through support from the newly created AbbVie COVID-19 Community Resilience Fund, these organizations will help front-line healthcare workers and vulnerable populations in hard-hit communities.
  • The COVID-19 Community Resilience Fund is part of AbbVie's broader $35 million philanthropic contribution to COVID-19 relief efforts that also include donations to partners International Medical Corps, Direct Relief and Feeding America.
  • A complete list of COVID-19 Community Resilience Fund donations is below.
  • In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics

Retrieved on: 
Wednesday, May 20, 2020
Life sciences, Biotechnology, Articles, Specialty drugs, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Regulus Therapeutics, AbbVie Inc.

The proceeds from the Series A financing will be used to develop and commercialize three cancer therapies discovered by Zentalis, in addition to potential future candidates, in China.

Key Points: 
  • The proceeds from the Series A financing will be used to develop and commercialize three cancer therapies discovered by Zentalis, in addition to potential future candidates, in China.
  • Anthony Sun, MD, CEO of Zentalis, will serve as CEO of Zentera.
  • The launch of Zentera is a key milestone in our global clinical development strategy, commented Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals and Chief Executive Officer at Zentera Therapeutics.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics

Retrieved on: 
Wednesday, May 20, 2020
Life sciences, Biotechnology, Articles, Specialty drugs, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Regulus Therapeutics, AbbVie Inc.

The proceeds from the Series A financing will be used to develop and commercialize three cancer therapies discovered by Zentalis, in addition to potential future candidates, in China.

Key Points: 
  • The proceeds from the Series A financing will be used to develop and commercialize three cancer therapies discovered by Zentalis, in addition to potential future candidates, in China.
  • Anthony Sun, MD, CEO of Zentalis, will serve as CEO of Zentera.
  • The launch of Zentera is a key milestone in our global clinical development strategy, commented Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals and Chief Executive Officer at Zentera Therapeutics.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Protein Therapeutics Market 2020-2024 | Increased Demand for mAbs to Boost Growth | Technavio

Retrieved on: 
Wednesday, May 20, 2020
Health, General Health, Companies, Life sciences, Pfizer, AbbVie Inc., Sanofi, AstraZeneca, Monoclonal antibodies

Our protein therapeutics market report covers the following areas:

Key Points: 
  • Our protein therapeutics market report covers the following areas:
    This study identifies the development of novel therapies using innovative technologies as one of the prime reasons driving the protein therapeutics market growth during the next few years.
  • We provide a detailed analysis of vendors operating in the protein therapeutics market, including some of the vendors such as AbbVie Inc., Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novo Nordisk AS, Pfizer Inc., and Sanofi.
  • Backed with competitive intelligence and benchmarking, our research reports on the protein therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Halozyme To Receive $15 Million Milestone Payment From Janssen

Retrieved on: 
Thursday, May 14, 2020
Companies, Biotechnology companies, Life sciences, AbbVie Inc., Johnson & Johnson, Baxalta, Bristol-Myers Squibb, Janssen Biotech, Janssen, Halozyme, Inc.

SAN DIEGO, May, 14, 2020 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies.

Key Points: 
  • SAN DIEGO, May, 14, 2020 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies.
  • Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.
  • Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success.
  • Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx.

AbbVie to Present at the UBS Virtual Healthcare Conference

Retrieved on: 
Thursday, May 14, 2020
Companies, AbbVie Inc., UBS

NORTH CHICAGO, Ill., May 14, 2020 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Virtual Healthcare Conference on Wednesday, May 20, 2020.

Key Points: 
  • NORTH CHICAGO, Ill., May 14, 2020 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Virtual Healthcare Conference on Wednesday, May 20, 2020.
  • Michael Severino, M.D., vice chairman and president and Robert A. Michael, executive vice president and chief financial officer, will present at 9:50 a.m. Central time.
  • AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions.
  • AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Retrieved on: 
Tuesday, May 12, 2020
Science, Other Science, Research, Pharmaceutical, General Health, Health, Infectious diseases, Other Health, Chemical compounds, Chemistry, Organic compounds, Cyclopropanes, Cyclopentanes, Sulfonamides, Carbamates, Ethers, Glecaprevir, AbbVie Inc., Protease inhibitor, Liver disease

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020 at 9:45 a.m.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020 at 9:45 a.m.
  • A live webcast of the fireside chat will be accessible by visiting the Events and Presentations section on the Investors page of Enantas website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection.